Markus Aly

The effect of sample size on polygenic hazard models for prostate cancer

This paper evaluates how sample size affects polygenic hazard score models for prostate cancer, finding that 20-30k samples are needed for discovery models, but 10k suffice if SNPs are pre-established.

A genetic hazard score to personalize prostate cancer screening, applied to population data

The paper evaluates a polygenic hazard score for prostate cancer screening, showing it improves positive predictive value by adjusting screening age based on genetic risk.

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis

This study profiles cell-free DNA in metastatic prostate cancer patients, identifying genomic alterations, microsatellite instability, and clonal hematopoiesis as potential biomarkers.

A genetic risk score to guide age-specific, personalized prostate cancer screening

This paper develops a genetic risk score to personalize prostate cancer screening age based on polygenic hazard scores and validates its predictive power in a separate dataset.